Q-omics provides the consensus-scored SNX18P9 profile across patient tissues and cancer cell-line models. SNX18P9 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, SNX18P9 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, SNX18P9 RNA expression shows 12,298 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, THCA, and THYM as cancer lineages where SNX18P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNX18P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNX18P9 survival associations across molecular data types. SNX18P9 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNX18P9 RNA expression–survival associations across cancer types. High SNX18P9 expression shows unfavorable associations in LGG, ESCA and THCA, but favorable associations in SKCM, KIRC and STAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for SNX18P9 RNA expression.
This table summarizes SNX18P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNX18P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNX18P9 shows lower tumor expression in THCA, BRCA, COAD, UCEC and HNSC and higher tumor expression in KICH. The THCA box plot shows higher SNX18P9 RNA expression in normal versus tumor tissue (log2 FC = −0.168, t-test p < 0.001).
This table shows molecular features associated with SNX18P9 in patient tissues and cancer cell lines. In patient samples, SNX18P9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
